---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-137689"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T13:03:06.428582+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Akebia Q1 net loss $26.2M; Auryxia revenue $34.8M; vadadustat approved in 32 countries

## Summary
- Net loss of $26.2M improved from $62.4M in Q1 2022; total revenue $40.1M vs $61.7M.
- Auryxia net product revenue $34.8M, down 15.9% YoY; company reaffirms 2023 guidance $175-180M.
- European Commission approved Vafseo (vadadustat) for anemia in CKD dialysis patients; approved in 32 countries.
- Expects FDA Formal Dispute Resolution response within next 30 days; positive alternative dosing study results.
- Cash $57.0M; expects to fund operations for at least 12 months with cash and Auryxia revenue.

## SEC filing metadata
- accession: 0001193125-23-137689
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/0001193125-23-137689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/d439043d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-137689
- JSON: https://secwatch.observer/filing/0001193125-23-137689.json
- Plain text: https://secwatch.observer/filing/0001193125-23-137689.txt

## Key facts
- Earnings Releases
  Akebia Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $40.1 million, net income $(26.2) million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $40.1 million
  - Net income: $(26.2) million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue was $40.1 million in the first quarter of 2023 compared to $61.7 million for the first quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000119312523137689/0001193125-23-137689-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.